Genmab A/S (NASDAQ:GMAB) Given Buy Rating at HC Wainwright

Posted by Geri Gentry on Jun 23rd, 2026

Genmab A/S (NASDAQ:GMAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $38.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 48.38% from the stock’s previous close.

Several other equities research analysts have also commented on GMAB. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Guggenheim reduced their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Finally, Wolfe Research initiated coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.93.

View Our Latest Stock Analysis on GMAB

Genmab A/S Stock Up 1.3%

Genmab A/S stock opened at $25.61 on Tuesday. Genmab A/S has a fifty-two week low of $20.23 and a fifty-two week high of $35.43. The stock has a market cap of $15.97 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.50 and a beta of 0.85. The firm’s 50-day simple moving average is $26.44 and its 200 day simple moving average is $28.95. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Paradigm Biocapital Advisors LP bought a new stake in shares of Genmab A/S in the third quarter valued at $117,063,000. Orbis Allan Gray Ltd raised its stake in Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after acquiring an additional 3,340,456 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the last quarter. First Trust Advisors LP lifted its holdings in Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares during the last quarter. Finally, Pictet Asset Management Holding SA bought a new position in Genmab A/S during the fourth quarter worth about $33,835,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.